Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 3 April 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: 15 January 2025
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
School-based interventions: physical and mental health and wellbeing promotionStatus:In developmentExpected publication date: TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC